This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Jeff Cislini Biography and Net Worth

General Counsel of Revolution Medicines

Jeff focused on corporate law early in his career because he was looking for an opportunity to bring legal expertise to complex business challenges. The ability to meet these challenges as part of a team that directly impacts the lives of patients drew Jeff to biotech.

He has approximately 20 years of experience and brings a pragmatic approach to practicing law, striving to interpret and discuss complex legal concepts in a coherent manner that results in actionable business advice.

Jeff comes to RevMed from Atara Biotherapeutics, where he most recently served as a Vice President and had responsibility for a broad range of legal matters, including corporate, contracts and employment. Prior to Atara, Jeff worked for a number of years as outside counsel focused on general corporate representation and transactional advice at the law firms of O’Melveny & Myers and Wilson Sonsini Goodrich & Rosati.

Jeff holds a JD from Harvard Law School and a BAS from Stanford University with dual majors in Land Resources Planning and Economics. He is a member of the California bar.

What is Jeff Cislini's net worth?: The estimated net worth of Jeff Cislini is at least $2.60 million as of October 11th, 2024. Mr. Cislini owns 45,634 shares of Revolution Medicines stock worth more than $2,604,332 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Cislini may own. Learn More about Jeff Cislini's net worth.
How do I contact Jeff Cislini?: The corporate mailing address for Mr. Cislini and other Revolution Medicines executives is 700 Saginaw Drive, Redwood City CA, 94063. Revolution Medicines can also be reached via phone at 650-481-6801 and via email at [email protected]. Learn More on Jeff Cislini's contact information.
Has Jeff Cislini been buying or selling shares of Revolution Medicines?: During the past quarter, Jeff Cislini has sold $301,020.00 in shares of Revolution Medicines stock. Most recently, Jeff Cislini sold 6,000 shares of the business's stock in a transaction on Friday, October 11th. The shares were sold at an average price of $50.17, for a transaction totalling $301,020.00. Following the completion of the sale, the general counsel now directly owns 45,634 shares of the company's stock, valued at $2,289,457.78. Learn More on Jeff Cislini's trading history.
Who are Revolution Medicines' active insiders?: Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?: In the last twelve months, insiders at the sold shares 30 times. They sold a total of 272,325 shares worth more than $11,628,071.51. The most recent insider tranaction occured on October, 14th when insider Stephen Michael Kelsey sold 16,666 shares worth more than $824,800.34. Insiders at Revolution Medicines own 8.0% of the company. Learn More about insider trades at Revolution Medicines.
Information on this page was last updated on 10/14/2024.

Jeff Cislini Insider Trading History at Revolution Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/11/2024	Sell	6,000	$50.17	$301,020.00	45,634
7/9/2024	Sell	2,399	$40.83	$97,951.17	47,088
6/26/2024	Sell	2,000	$38.47	$76,940.00	49,487
3/27/2024	Sell	1,500	$30.99	$46,485.00	54,374
3/18/2024	Sell	1,252	$31.58	$39,538.16	55,874
1/22/2024	Sell	1,500	$27.00	$40,500.00	36,126
12/18/2023	Sell	1,229	$25.90	$31,831.10	37,284
11/20/2023	Sell	1,500	$21.70	$32,550.00	38,513
9/28/2023	Sell	2,000	$28.20	$56,400.00	40,013
9/18/2023	Sell	1,214	$31.31	$38,010.34	42,013
7/31/2023	Sell	1,500	$26.02	$39,030.00	43,227
6/20/2023	Sell	1,239	$25.14	$31,148.46	44,727

Jeff Cislini Buying and Selling Activity at Revolution Medicines

Revolution Medicines Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $57.07

$56.01

$57.97

50 Day Range

MA: $49.99

$41.97

$60.60

2 Week Range

Now: $57.07

$20.51

$62.40

Volume

843,096 shs

Average Volume

1,698,615 shs

Market Capitalization

$9.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

When it comes to NVDA… “acceleration cycles” are the key

From DTI | Ad

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!